205 results
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
, launch timing, pricing, sales ramp, market share, market exclusivity, research and development expenses, sales and marketing expenses, general … and administrative expenses, effective tax rate and utilization of federal net operating losses, federal research and development expenses and other relevant
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
assets
Deferred tax asset
In-process research and development asset (note 5)
Total non-current assets
Total Assets
Liabilities and Shareholders’ Equity … )
Three-month periods ended
March 31,
Revenues
Expenses:
Research and development
Research tax credits
General and administrative
Total operating expenses
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
and cost of the research and development activities of camlipixant;
our aim to complete the validation of the VitaloJAK for cough frequency measurement … success of current research and development activities;
our achievement of development and commercial milestones, including forecasted preclinical
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
to finance the Company’s operating activities, mainly the research and development activities associated with its product candidate camlipixant (BLU-5937 … share) for the same period in 2022.
Research and Development Expenses: Research and development expenses, net of research tax credits, amounted to US
6-K
EX-99.2
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
).
“Research Programs” means all research and development programs, pre-clinical and clinical trials, pre-clinical and clinical studies and the results … ), or any research, development, distribution, sale, supply, license, importation, exportation, marketing, co-promotion or manufacturing activities
6-K
EX-99.1
y8i8 66gceqv2egf8jg
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.1
bzs3m9tkijy6 hc29c
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
6-K
EX-99.2
rku8uj p2us
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
qt900
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
bsh o8qqa
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
F-10
loywji8v
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.1
lz4dxff k6
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.2
1ybiwdoxl3e
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
of45303fz6jybbzt1ej
10 Aug 22
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
4:31pm
6-K
EX-99.1
2g4uy3 wazfl2ae
18 Jul 22
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
4:05pm
SUPPL
q6inp 0znb
15 Jul 22
Supplemental materials (foreign)
7:01am
6-K
EX-99.1
o4k8owlma373j vq
14 Jul 22
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
4:46pm
SUPPL
q0cadsq
13 Jul 22
Supplemental materials (foreign)
5:01pm
6-K
EX-99.1
nyab96l7 ng
13 Jul 22
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
4:25pm
6-K
EX-99.1
1klnv p2tf2wc5ey
11 May 22
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
5:23pm